Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).

[1]  D. Candinas,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand on NK Cells Protects From Hepatic Ischemia-Reperfusion Injury , 2014, Transplantation.

[2]  P. Chiusolo,et al.  Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  B. Koneru,et al.  Does Liver Ischemic Preconditioning in Brain Death Donors Induce Kidney Preconditioning? A Retrospective Analysis , 2014, Transplantation.

[4]  W. Wiktor-Jedrzejczak,et al.  Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice , 2014, Bone Marrow Transplantation.

[5]  A. Santoro,et al.  The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo , 2013, Leukemia.

[6]  R. Bouabdallah,et al.  Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT , 2013, Bone Marrow Transplantation.

[7]  Yu-Hong Chen,et al.  Incidence of Invasive Fungal Disease After Unmanipulated Haploidentical Stem Cell Transplantation Was Significantly Higher Than That After HLA-Matched Sibling Transplantation , 2013 .

[8]  M. Çetin,et al.  Pretransplant iron overload may be associated with increased risk of invasive fungal pneumonia (IFP) in patients that underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[9]  A. Nagler,et al.  Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. , 2013, Blood.

[10]  T. Egberts,et al.  Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients , 2012, Antimicrobial Agents and Chemotherapy.

[11]  P. Johann,et al.  Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation , 2012, BMC Infectious Diseases.

[12]  B. Koneru,et al.  Review of Randomized Clinical Trials of Donor Management and Organ Preservation in Deceased Donors: Opportunities and Issues , 2012, Transplantation.

[13]  C. Girmenia,et al.  Safety and interactions of new antifungals in stem cell transplant recipients , 2012, Expert opinion on drug safety.

[14]  A. McLachlan,et al.  Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration , 2012, Antimicrobial Agents and Chemotherapy.

[15]  A. Erbacher,et al.  Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis , 2012, BMC Infectious Diseases.

[16]  E. O'Mara,et al.  Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension , 2012, Antimicrobial Agents and Chemotherapy.

[17]  V. Martín,et al.  Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT , 2012, Bone Marrow Transplantation.

[18]  C. Meisner,et al.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study , 2012, Haematologica.

[19]  V. Anttila,et al.  Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[20]  C. Heussel,et al.  Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation , 2011, British journal of haematology.

[21]  J. Cayuela,et al.  Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high‐risk hematological diseases , 2011, Transplant infectious disease : an official journal of the Transplantation Society.

[22]  G. Papanicolaou,et al.  Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  C. Craddock,et al.  Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia , 2011, Leukemia.

[24]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[25]  M. Territo,et al.  Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  F. Farowski,et al.  Therapeutic Drug Monitoring of Voriconazole and Posaconazole , 2011, Pharmacotherapy.

[28]  J. Dipersio,et al.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. , 2010, Blood.

[29]  M. Aydoğdu,et al.  Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload , 2010, Bone Marrow Transplantation.

[30]  J. Klein,et al.  Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Ş. Akı,et al.  Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation. , 2010, Transplantation proceedings.

[32]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  B. Guglielmo,et al.  Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[34]  P. Chevallier,et al.  Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  T. Barbui,et al.  Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  A. Ibatici,et al.  Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients , 2009, Bone Marrow Transplantation.

[37]  C. Lombardo,et al.  Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. , 2009, Blood.

[38]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  K. Marr,et al.  Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  Q. Jiang,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  L. Pagano,et al.  Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  E. Shpall,et al.  Infections in 100 Cord Blood Transplantations: Spectrum of Early and Late Posttransplant Infections in Adult and Pediatric Patients 1996-2005 , 2007, Medicine.

[44]  Y. Kanda,et al.  Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  M. Boeckh,et al.  Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  K. Sullivan,et al.  Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[48]  H. Einsele,et al.  Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantati , 2006, Blood.

[49]  Wei Han,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies , 2006, Bone Marrow Transplantation.

[50]  J. Sierra,et al.  Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[51]  F. Gao,et al.  Disruption of P-Selectin Signaling Modulates Cell Trafficking and Results in Improved Outcomes after Mouse Warm Intestinal Ischemia and Reperfusion Injury , 2005, Transplantation.

[52]  J. Wagner,et al.  Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[55]  M. Maris,et al.  Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. , 2003, Blood.

[56]  M. Boeckh,et al.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. , 2002, Blood.

[57]  M. Salavert,et al.  Early infections in adult patients undergoing unrelated donor cord blood transplantation , 2002, Bone Marrow Transplantation.

[58]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[60]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[61]  David H. Gustafson,et al.  Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes , 1976 .

[62]  T. Lamparelli,et al.  Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[63]  G. Rossi,et al.  Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study , 2011, Bone Marrow Transplantation.

[64]  Yu Wang,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[65]  L. Kanz,et al.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. , 2008, Blood cells, molecules & diseases.

[66]  C. Webb,et al.  The Delphi technique: a methodological discussion. , 1994, Journal of advanced nursing.